Nervous System Diseases Clinical Trial
Official title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy
HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during the first 12-months of the study. All participants will be eligible to receive 4 doses of CAP-1002 for an additional 12 months as part of an open-label extended assessment period.
Up to 102 eligible study subjects will participate in this two cohort study. Cohort A will enroll approximately 58 subjects randomized in a 1:1 ratio (active:placebo). Subjects randomized to the active treatment group in Cohort A will receive CAP-1002A (manufactured at Capricor's manufacturing facility in Los Angeles, CA). Once Cohort A enrollment is completed, Cohort B enrollment will begin. Cohort B will enroll approximately 44 participants randomized in a 1:1 ratio (active:placebo). Subjects randomized to the active treatment group in Cohort B will receive CAP-1002B (manufactured at Capricor's manufacturing facility in San Diego, CA). Both cohorts will include visits at Screening, Baseline/Day 1, Month 1, and Months 3, 6, 9, and 12. Subjects will receive IV infusions of CAP-1002 or placebo on Day 1 and Months 3, 6, and 9. All subjects will then be eligible to receive additional IV infusions of CAP-1002 at Month 12, 15, 18, and 21 as part of the open-label phase of the study. A primary analysis of efficacy and safety will be performed for each individual cohort at Month 12 following 4 administrations of CAP-1002 or placebo. The primary efficacy endpoint is the mean change from baseline in upper limb function as assessed by Performance of the Upper Limb test, version 2.0 [PUL 2.0] Total Score at the 12-month time point. Secondary endpoints evaluated at the 12-month time point include assessment of changes in cardiac muscle function and structure by cardiac magnetic resonance imaging [cMRI], changes in hand-to-mouth function [eat 10-bites assessed by the Duchenne Video Assessment (DVA)], quality of life assessments, and biomarker analysis for creatine kinase MB isoenzyme (CK-MB). Safety evaluations will include adverse events, concomitant medications, physical exam, vital signs, and clinical laboratory testing. Following the initial 4 infusions in Cohort A or Cohort B, all subjects will be eligible to participate in a 12-month open label extended assessment period and receive up to 4 additional IV infusions of CAP-1002 once every 3 months. An analysis of extended safety and efficacy will be conducted after all subjects have completed the Month 24 visit. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05086809 -
Investigation of an Updated Bone-anchored Sound Processor
|
N/A | |
Completed |
NCT05080777 -
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
|
N/A | |
Recruiting |
NCT03222375 -
SQUEDâ„¢ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
|
N/A | |
Completed |
NCT03295786 -
Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT01922258 -
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
|
Phase 3 | |
Completed |
NCT01915368 -
Determining Optimal Post-Stroke Exercise (DOSE)
|
N/A | |
Terminated |
NCT03270189 -
Effect of the Visual Information Change in Functional Dystonia
|
N/A | |
Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
Suspended |
NCT04912115 -
Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia
|
Phase 2 | |
Completed |
NCT03994822 -
pRESET for Occlusive Stroke Treatment
|
N/A | |
Completed |
NCT03336645 -
Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan
|
Phase 3 | |
Completed |
NCT04283253 -
Predictors of Response in Chronic Stroke
|
N/A | |
Not yet recruiting |
NCT06048523 -
Prospective Cohort Study of Neurogenetic Diseases
|
N/A | |
Completed |
NCT02684825 -
Detection of Silent Atrial Fibrillation aFter Ischemic StrOke
|
N/A | |
Active, not recruiting |
NCT02284126 -
Topical Vancomycin for Neurosurgery Wound Prophylaxis
|
Phase 3 | |
Completed |
NCT05815836 -
Precision Medicine in Stroke
|
||
Completed |
NCT00739518 -
Refinement and Assessment of New Magnetic Resonance Imaging Technologies for Neurological Exams
|
N/A | |
Recruiting |
NCT03678194 -
Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application
|
N/A | |
Recruiting |
NCT04698421 -
Collection of Biological Samples From Patients With Rare Neurological Diseases
|